Neurocrine Biosciences
NBIX
#1305
Rank
$13.24 B
Marketcap
$133.12
Share price
1.39%
Change (1 day)
32.16%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Operating Margin for Neurocrine Biosciences (NBIX)

Operating Margin as of March 2024 (TTM): 14.36%

According to Neurocrine Biosciences 's latest financial reports and stock price the company's current Operating Margin is 14.36%. At the end of 2022 the company had an Operating Margin of 14.37%.

Operating Margin history for Neurocrine Biosciences from 2003 to 2010

Operating Margin at the end of each year

Year Operating Margin Change
202214.37%60.62%
20218.95%-12.31%
202010.20%72.9%
20195.90%21.9%
20184.84%-105.49%
2017-88.19%-90.62%
2016-940.60%109.1%
2015-449.84%
2013-1,578.97%-16797.76%
20129.46%-80.52%
201148.53%-304.06%
2010-23.78%-98.53%
2009-1,614.83%-27.56%
2008-2,229.26%-86.84%
2007-16,936.19%6098.17%
2006-273.25%1425.49%
2005-17.91%-66.61%
2004-53.65%147.89%
2003-21.64%-95.87%
2002-523.89%487.29%
2001-89.21%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
34.61% 141.02%๐Ÿ‡บ๐Ÿ‡ธ USA
18.65% 29.87%๐Ÿ‡บ๐Ÿ‡ธ USA
24.66% 71.73%๐Ÿ‡บ๐Ÿ‡ธ USA
27.34% 90.39%๐Ÿ‡บ๐Ÿ‡ธ USA
-1,576.98%-11,081.75%๐Ÿ‡บ๐Ÿ‡ธ USA
-9.64%-167.13%๐Ÿ‡บ๐Ÿ‡ธ USA
-2,465.05%-17,266.09%๐Ÿ‡บ๐Ÿ‡ธ USA
27.89% 94.22%๐Ÿ‡ฌ๐Ÿ‡ง UK

What is a company's Operating Margin

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.